Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 6, 2005, Pages 871-883

  Anderson, Albert M L ^a   Bartlett, John A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abacavir; AIDS; Fixed dose combination; HIV; Lamivudine

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALCOHOL; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; CORTICOSTEROID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; HEADACHE; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LACTIC ACIDOSIS; LEUKOPENIA; LIPOATROPHY; LYMPHOCYTOPENIA; MALAISE; METABOLIC DISORDER; MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRURITUS; SLEEP DISORDER; TACHYCARDIA; THROMBOCYTOPENIA; URTICARIA; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

ANIMALS; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE;

EID: 28944447626     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.3.6.871     Document Type: Article

References (89)

1. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000).
2. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J. Acquir. Immune. Defic. Syndr. 23(5), 386-395 (2000).
3. Ammassari A, Murri R, Pezzotti P et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune. Defic. Syndr. 28(5), 445-449 (2001).
4. Howard AA, Arnsten JH, Lo Y et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16(16), 2175-2182 (2002).
5. Miller LG, Huffman HB, Weidmer BA, Hays RD. Patient preferences regarding antiretroviral therapy. Int. J. STD AIDS 13(9), 593-601 (2002).
6. Bass D, Smith MF. HIV patients prefer once-daily regiments. 14th International AIDS Conference. Barcelona, Spain (2002).
7. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int. J. STD AIDS 14(Suppl. 1), 34-36 (2003).
8. Epivir® (lamivudine). GlaxoSmithKline. Package insert (2004).
9. Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53(4), 657-680 (1997).
10. Ziagen® (abacavir). GlaxoSmithKline. Package insert (2004).
11. Hervey PS, Perry CM. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60(2), 447-479 (2000).
12. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent antihuman immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41(5), 1099-1107 (1997).
13. Daluge SM, Good SS, Faletto MB et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective antihuman immunodeficiency virus activity. Antimicrob. Agents Chemother. 41(5), 1082-1093 (1997).
14. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 65(2), 285-302 (2005).
15. Epzicom® package insert. GlaxoSmithKline (2004).
16. Baker K, Lou Y, Yuen G, Murray S, Stein D. The bioequivalence and effect of food of a new once-a-day fixed dose combination tablet of abacavir (ABC) and lamivudine (3TC). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC, USA, October 30-November 2 (2004).
17. Piliero P, Shachoy-Clark A, Para M et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA10905). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, September 14-17 (2003).
18. Moore KH, Barrett JE, Shaw S et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13(16), 2239-2250 (1999).
19. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis. 39(7), 1038-1046 (2004).
20. Rodriguez-French A, Boghossian J, Gray GE et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr. 35(1), 22-32 (2004).
21. Gathe JC Jr, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18(11), 1529-1537 (2004).
22. Bartlett JA, Johnson J, Herrera G et al. Initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine: 96 week results from the CLASS study. XV International AIDS Conference. Bangkok, Thailand (2004).
23. Podzcamer D, Ferrer E, Sanchez P et al. A randomized comparison between abacavir and stavudine, both combined with lamivudine/efavirenz, in antiretroviral-naive patients: final 96 week results of the ABCDE study. 12th Conference on retroviruses and opportunistic infections. Boston, USA, February 22-25 (2005).
24. Moyle GJ, Dejesus E, Cahn P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily In Antiretroviral Combination Study. J. Acquir. Immune. Defic. Syndr. 38(4), 417-425 (2005).
25. Sosa N, Hill-Zabala C, DeJesus E et al. Abacavir + lamivudine fixed dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-1-infected subjects (ESS30008). 12th conference on retroviruses and opportunistic infections. MA, USA, February 22-25 (2005).
26. Watson M, Hill-Zabala C, Sosa N, DeJesus E, Florance A. Patient satisfaction with abacavir (ABC)-lamivudine (3TC) fixed dose combination (FDC) tablet once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients (ESS30008). Third International AIDS Society Meeting on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
27. Clumeck N, Lamarca A, Fu K et al. Safety and efficacy of a once daily (OAD) fixed-dose combination (FDC) of ABC/3TC (FDC arm) versus ABC twice daily (BID) and 3TC OAD as separate entities (SE arm) in ART-experienced HIV-1 infected patients. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, October 30-November 2 (2004).
28. Gallant JE, Rodriguez AE, Weinberg W et al. Efficacy and safety of once-daily abacavir/lamivudine fixed-dose combination (ABC/3TC) + efavirenz (EFV): ESS30009 planned 48 week analysis. Third International AIDS Society Meeting on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
29. Gallant JE, Rodriguez AE, Weinberg W et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, September 14-17 (2003).
30. Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the TONUS study. 11th Conference on Retroviruses and Opportunistic Infections. CA, USA, February 8-11 (2004).
31. Schuurman R, Nijhuis M, van LR et al. Rapid changes in human immunodeficiency virus Type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171(6), 1411-1419 (1995).
32. Kavlick MF, Shirasaka T, Kojima E et al. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral. Res. 28(2), 133-146 (1995).
33. Wainberg MA, Drosopoulos WC, Salomon H et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271(5253), 1282-1285 (1996).
34. Pluda JM, Cooley TP, Montaner JS et al. A Phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171(6), 1438-1447 (1995).
35. Van Leeuwen R, Katlama C, Kitchen V et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a Phase I/II study. J. Infect. Dis. 171(5), 1166-1171 (1995).
36. Schmit JC, Van LK, Ruiz L et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 12(15), 2007-2015 (1998).
37. Schmit JC, Cogniaux J, Hefmans P et al. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus Type 1 patient strain. J. Infect. Dis. 174(5), 962-968 (1996).
38. Van Laethem K, Witvrouw M, Balzarini J et al. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS 14(4), 469-471 (2000).
39. Rakik A, It-Khaled M, Griffin P, Thomas TA, Tisdale M, Kleim JP. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. J. Acquir. Immune. Defic. Syndr. 22(2), 139-145 (1999).
40. Hertogs K, Bloor S, De V et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 44(3), 568-573 (2000).
41. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob. Agents Chemother. 46(1), 89-94 (2002).
42. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus Type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41(5), 1094-1098 (1997).
43. Harrigan PR, Stone C, Griffin P et al. Resistance profile of the human immunodeficiency virus Type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J. Infect. Dis. 181(3), 912-920 (2000).
44. Lanier ER, It-Khaled M, Scott J et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9(1), 37-45 (2004).
45. Brun-Vezinet F, Descamps D, Ruffault A et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17(12), 1795-802 (2003).
46. Craig C, Stone C, Bonny T et al. Analysis of virologic failure in a clinical trial of abacavir once daily versus twice daily with lamivudine and efavirenz. 11th Conference an Retroviruses and Opportunistic Infections. CA, USA, February 8-11 (2004).
47. Irlbeck D, Rouse E, Castillo S et al. Treatment emergent mutations for previously naive HIV-infected adults failing ZDV/3TC/EFV and ABC/3TC/EFV. 11th Conference on Retroviruses and Opportunistic Infections. CA, USA, February 8-11 (2004).
48. Hernandez J, Williams V, Sawyer R et al. The rate of hypersensitivity reactions to abacavir is similar in under-represented populations and incarcerated subjects. Programs and Abstracts of the 5th International Congress on the Therapy of HIV Infection (Glasgow). (2000).
49. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10), 1603-1614 (2001).
50. James A, Johann-Liang R. Increased rate and severity of abacavir-associated hypersensitivity reaction in randomized controlled clinical trials. 12th Conference on retroviruses and opportunistic infections. Boston, USA, February 22-25 (2005).
51. Cutrell AG, Hernandez JE, Fleming JW et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann. Pharmacother. 38(12), 2171-2172 (2004).
52. Hetherington S, Steel H, Naderer O, Cutrell A, Powell W, Sykes R. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. 7th Conference on Retroviruses and Opportunistic Infections. CA, USA, January 30-February 4 (2000).
53. Hewitt RG. Abacavir hypersensitivity reaction. Clin. Infect. Dis. 34(8), 1137-1142 (2002).
54. Dargere S, Verdon R, Bouhier K, Bazin C. Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction. AIDS 16(12), 1696-1697 (2002).
55. Glaxo Wellcome. Fatal hypersensitivity reactions, respiratory symptoms, and Ziagen. Dear Healthcare Provider Letter. Media Release. January (2000).
56. Wit FW, Wood R, Horban A et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 15(18), 2423-2429 (2001).
57. Blanckenberg DH, Wood R, Horban A et al. Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects. AIDS 18(4), 631-640 (2004).
58. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
59. Symonds W, Cutrell A, Edwards M et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin. Ther. 24(4), 565-573 (2002).
60. Bartlett JA, Mole LA, Fusco JS, Baker RK, Nordstrom BL. Frequency of abacavir (ABC) hypersensitivity reactions (HSR), rechallenge reactions, and HSR-attributable outcomes are similar with the use of Ziagen or Trizivir: final results from the Trizivir Epidemiology Study. Third International AIDS Society Meeting on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
61. Brothers C, Cutrell A, Zhao H et al. Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash alone is not sufficient to diagnose the reaction. 12th Conference on retroviruses and opportunistic infections. Boston, USA, February 22-25 (2005).
62. Hernandez J, Gordon D, Cutrell A et al. Abacavir (ABC) has a similar safety profile when administered once daily (QD) or twice daily (BID) in combination with lamivudine (3TC) and efavirenz (EFV) once daily to antiretroviral (ART)-naive, HIV infected adults. XV International AIDS Conference. Bangkok, Thailand, July 11-16 (2004).
63. Yeni P, Sutherland-Phillips D, Wannamaker P et al. Reported incidence and severity of suspected abacavir hypersensitivity reactions (HSR) through at least 6 weeks in a large, controlled clinical trial using a once-daily (OAD) abacavir 600mg/lamivudine 300mg tablet (ABC/3TC FDC) dual nucleoside backbone with a boosted protease inhibitor: The KLEAN Study. Third International AIDS Society Meeting on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
64. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16(16), 2223-2225 (2002).
65. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir of zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. 38(2), 263-270 (2004).
66. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 345(8947), 460-461 (1995).
67. Staszewski S, Katlama C, Harrer T et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 12(16), F197-F202 (1998).
68. Steel H, Hetherington S, Pearce G et al. Abacavir safety and tolerability: experience from over 25,000 adults and chldren. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27 (1999).
69. Del Guidice P, Vandenbos F, Perrin C, Bernard E, Marq L, Dellamonica P. Sweet's syndrome following abacavir therapy. J. Am. Acad. Dermatol. 51(3), 474-475 (2004).
70. Podzcamer D, Ferrer E, Sanchez P et al. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48-week results ofa randomized open and multicenter tiral (ABCDE study). 11th Conference on Retroviruses and Opportunistic Infections. CA, USA, February 8-11 (2004).
71. Shlay JC, Visnegarwala F, Bartsch G et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J. Acquir. Immune. Defic. Syndr. 38(2), 147-155 (2005).
72. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J. Acquir. Immune. Defic. Syndr. 33(1), 22-28 (2003).
73. Cherry CL, Lal L, Thompson KA et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J. Acquir. Immune. Defic. Syndr. 38(3), 263-267 (2005).
74. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 19(1), 15-23 (2005).
75. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. J. Am. Med. Assoc. 288(2), 207-215 (2002).
76. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18(7), 1029-1036 (2004).
77. Moyle GJ. The impact of abacavir on lipids and lipodystrophy. AIDS Read. 15(2), 62-66 (2005).
78. Tashima K, Kumar P, Rodriguez-French A et al. Gender and race subgroup analysis in a prospective study of hyperlipidemia in ART-naive subjects taking combivir/abacavir (CCM/ABC) vs. combivir/nelfinavir (COM/NFV) vs. stavudine/lamivudine/nelfinavir (d4T/3TC/NFV). 2nd IAS Conference on Pathogenesis and Treatment. Paris, France, July 13-16 (2003).
79. Fischl M, Greenberg S, Clumeck N et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naive subjects. 12th World AIDS Conference. Geneva, Switzerland, June 28-July 3 (1998).
80. Hicks C, Fischl M, Greenberg S et al. Ziagen (abacavir, ABC) combined with 3TC & ZDV provides a potent & durable response through 48 weeks in HIV-1-infected antiretroviral therapy (ART)-naive adults (CNA3003). 37th Annual Meeting of the Infectious Disease Society of America. PA, USA, November 18-20 (1999).
81. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. J. Am. Med. Assoc. 285(9), 1155-1163 (2001).
82. Vibhagool A. Abacavir/combivir (ABC/COM) is comparable to indinavir/combivir (IDV/COM) in HIV-1-infected antiretroviral therapy naive adults: results of a 48-week open-label study (CNA3014). 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 8-11 (2001).
83. Matheron S, Descamps D, Boue F et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir. Ther. 8(2), 163-171 (2003).
84. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med. 349(11), 1036-1046 (2003).
85. Clumeck N, Goebel F, Rozenbaum W et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15(12), 1517-1526 (2001).
86. Katlama C, Fenske S, Gazzard B et al. TRIZAL study: switching from successful HAART to trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. 4(2), 79-86 (2003).
87. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J. Infect. Dis. 185(9), 1251-1260 (2002).
88. Panel on clinical practices for treatment of HIV infection convened by the department of health and human services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents (2005).
89. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus Type 1: recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37(1), 113-128 (2003).